Trials / Terminated
TerminatedNCT01888042
Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer
Phase II Study Assessing Everolimus as Fist Line Treatment in Patients With Metastatic Kidney Cancer of Bad Prognosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is a an open label, multicentric, phase II study assessing the efficacy of everolimus (given per os) as a first line treatment in kidney cancer of bad prognosis. 92 patients will be included (anticipated). The treatment by everolimus will continue until progression, significant toxicity or withdraw of consent
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | 10 mg (1 tablet of 10 mg) |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2013-06-27
- Last updated
- 2016-02-10
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01888042. Inclusion in this directory is not an endorsement.